FDA Approves Gemcitabine Intravesical System for Non-Muscle Invasive Bladder Cancer By Ogkologos - September 19, 2025 565 0 Facebook Twitter Google+ Pinterest WhatsApp Evidence for efficacy is based on the results from the Cohort 2 of SunRISe-1 study Source RELATED ARTICLESMORE FROM AUTHOR FDA Approves Allogeneic Regulatory T Cell-Based Immunotherapy with HSPC and T Cells-vldq for Use in Matched Donor HSCT for Adult Patients with Haematologic Malignancies Combination of mFOLFOX6/Bevacizumab Plus Atezolizumab Prolongs PFS Compared with Atezolizumab in First-Line Treatment of dMMR/MSI-H mCRC Use of YEARS Algorithm, D-dimer Levels, and Performing Risk-Dependent CT Pulmonary Angiography is Safe in Patients with Cancer and Suspected Pulmonary Embolism MOST POPULAR Savolitinib Shows Promise in Pulmonary Sarcomatoid Carcinoma and Other METex14-positive NSCLC... June 23, 2021 EMA Recommends to Extend Therapeutic Indications for Crizotinib in Paediatric Patients July 26, 2024 Risk of Anal Cancer Significantly Lower with Treatment for Anal High-Grade... June 22, 2022 New Study Finds Dogs Can Sniff Out Lung Cancer — And... April 10, 2019 Load more HOT NEWS Peer-to-peer match-funding initiative raises over £4 million for cancer research Adjuvant Abemaciclib Combined with Endocrine Therapy Improves IDFS in HR-Positive, HER2−Negative,... Low-Dose Adjuvant Aspirin Decreases Incidence of Recurrence Among Patients with Resected... Durvalumab Modestly Improves Survival in Advanced Biliary Tract Cancer
